{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:21:08Z","timestamp":1761488468090},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T00:00:00Z","timestamp":1277337600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s12185-010-0608-7","type":"journal-article","created":{"date-parts":[[2010,6,23]],"date-time":"2010-06-23T05:26:10Z","timestamp":1277270770000},"page":"5-11","source":"Crossref","is-referenced-by-count":5,"title":["Targeted treatment and new agents in follicular lymphoma"],"prefix":"10.1007","volume":"92","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,24]]},"reference":[{"key":"608_CR1","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447\u201352.","journal-title":"J Clin Oncol"},{"key":"608_CR2","first-page":"1013","volume":"110","author":"W Ozegowski","year":"1971","unstructured":"Ozegowski W, Krebs D. IMET 3393, (-[1-Methyl-5-bis-(\u03b2-chlor\u00e4thyl)-aminobenzimidazolyl-(2)]-butter s\u00e4urehydrochlorid, ein neues Zytostatikum aus der Reihi der Benzimidazol-Loste. Zbl Pharm. 1971;110:1013\u20139.","journal-title":"Zbl Pharm"},{"key":"608_CR3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","volume":"7","author":"D Strumberg","year":"1996","unstructured":"Strumberg D, Harstrick A, Doll K, Horffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs. 1996;7:415\u201321.","journal-title":"Anticancer Drugs"},{"key":"608_CR4","first-page":"132","volume":"10","author":"C Schwaenen","year":"1999","unstructured":"Schwaenen C, Karakas T, Schrader M. Bendamustine in induction of apoptosis in B-cell chronic lymphocytic leukemia. Ann Oncol. 1999;10:132 (Abstract).","journal-title":"Ann Oncol"},{"key":"608_CR5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309\u201317.","journal-title":"Clin Cancer Res"},{"key":"608_CR6","first-page":"640a","volume":"102","author":"LM Leoni","year":"2003","unstructured":"Leoni LM, Bailey B, Reifert J. SDX-105 (bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action. Blood. 2003;102:640a (Abstract 2363).","journal-title":"Blood"},{"key":"608_CR7","unstructured":"Leoni LM, Bailey B, Niemeyer CC, Kerfoot C, et al. In vivo and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res. 2004;45 (Abstract 1214)."},{"key":"608_CR8","first-page":"33","volume":"87","author":"KU Chow","year":"2002","unstructured":"Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002;87:33\u201343.","journal-title":"Haematologica"},{"key":"608_CR9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","volume":"12","author":"A Heider","year":"2001","unstructured":"Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin\u2019s lymphomas. Anticancer Drugs. 2001;12:725\u20139.","journal-title":"Anticancer Drugs"},{"key":"608_CR10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","volume":"128","author":"K Bremer","year":"2002","unstructured":"Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin\u2019s lymphomas. J Cancer Res Clin Oncol. 2002;128:603\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"key":"608_CR11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","volume":"132","author":"M Herold","year":"2006","unstructured":"Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO#19). J Cancer Res Clin Oncol. 2006;132:105\u201312.","journal-title":"J Cancer Res Clin Oncol"},{"key":"608_CR12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"28","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab refractory and alkylator-refractory, indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter single-agent study. J Clin Oncol. 2008;28:204\u201310.","journal-title":"J Clin Oncol"},{"key":"608_CR13","doi-asserted-by":"crossref","unstructured":"Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory indolent B-cell non-Hodgkin\u2019s lymphoma: results from a large multicenter study. Cancer. 2010;116:106\u2013114.","DOI":"10.1002\/cncr.24714"},{"key":"608_CR14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood.V114.22.2681.2681","volume":"114","author":"BD Cheson","year":"2009","unstructured":"Cheson BD, Friedberg JW, Kahl BS, van der Jagt RH, Tremmel L, Zaks T. Bendamustine produces durable responses with an acceptable long-term safety profile in patients with rituximab-refractory non-Hodgkin\u2019s lymphoma: a pooled analysis. Blood. 2009;114:1049 (Abstract #2681).","journal-title":"Blood"},{"key":"608_CR15","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran S, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:3383\u20139.","journal-title":"J Clin Oncol"},{"key":"608_CR16","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, et al. Bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma: a phase II multicenter study. J Clin Oncol. 2008;26:4473\u20139.","journal-title":"J Clin Oncol"},{"key":"608_CR17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.V114.22.405.405","volume":"114","author":"MJ Rummel","year":"2009","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009;114:168\u20139 (Abstract #405).","journal-title":"Blood"},{"key":"608_CR18","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867\u201374.","journal-title":"J Clin Oncol"},{"key":"608_CR19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676\u201384.","journal-title":"J Clin Oncol"},{"key":"608_CR20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:667\u201375.","journal-title":"J Clin Oncol"},{"key":"608_CR21","doi-asserted-by":"crossref","unstructured":"Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase II study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2009 (e-pub ahead of print).","DOI":"10.1182\/blood-2009-08-233155"},{"key":"608_CR22","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","volume":"27","author":"S Vos de","year":"2009","unstructured":"de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal zone B-cell lymphoma. J Clin Oncol. 2009;27:5023\u201330.","journal-title":"J Clin Oncol"},{"key":"608_CR23","doi-asserted-by":"crossref","first-page":"446s","DOI":"10.1200\/JCO.2008.18.8151","volume":"27","author":"J Matous","year":"2009","unstructured":"Matous J, Letzer J, Rosen P, et al. Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): dose-finding results of the VERTICAL study. J Clin Oncol. 2009;27:446s (Abstract 8550).","journal-title":"J Clin Oncol"},{"key":"608_CR24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2009-07-234179","volume":"114","author":"N Fowler","year":"2009","unstructured":"Fowler N, Kahl BS, Rosen P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory folicular lymphoma: encouraging activity in the phase 2 VERTICAL study. Blood. 2009;114:384\u20135 (Abstract #933).","journal-title":"Blood"},{"key":"608_CR25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.V114.22.381.381","volume":"114","author":"JW Friedberg","year":"2009","unstructured":"Friedberg JW, Vose JM, Kelly JL, et al. Bendamustine, bortezomib and rituximab in patients (pts) relapsed\/refractory indolent and mantle cell non-Hodgkin\u2019s lymphoma (NHL): a multicenter phase II clinical trial. Blood. 2009;114:381 (Abstract #924).","journal-title":"Blood"},{"key":"608_CR26","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Eetude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23:4117\u201326.","journal-title":"J Clin Oncol"},{"key":"608_CR27","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","volume":"111","author":"A Hagenbeek","year":"2008","unstructured":"Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial. Blood. 2008;111:5486\u201395.","journal-title":"Blood"},{"key":"608_CR28","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/blood.V114.22.1440.1440","volume":"114","author":"JW Friedberg","year":"2009","unstructured":"Friedberg JW, Vose JM, Kahl BS, et al. A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed\/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. Blood. 2009;114:1440\u20131 (Abstract #3742).","journal-title":"Blood"},{"key":"608_CR29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2009-02-205989","volume":"114","author":"G Salles","year":"2009","unstructured":"Salles G, Morschhauser F, Lamy T, et al. Phase I study of RO5072759 (GA101) in patients with relapsed\/refractory CD20+ non-Hodgkin\u2019s lymphoma (NHL). Blood. 2009;114:679 (Abstract #1704).","journal-title":"Blood"},{"key":"608_CR30","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","volume":"27","author":"F Morschhauser","year":"2009","unstructured":"Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin\u2019s lymphoma: phase I\/II results. J Clin Oncol. 2009;27:3346\u201353.","journal-title":"J Clin Oncol"},{"key":"608_CR31","doi-asserted-by":"crossref","unstructured":"Hagenbeek A, Fayad L, Delwail V, et al. Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma. Blood. 2009;114 (Abstract 935).","DOI":"10.1182\/blood.V114.22.935.935"},{"key":"608_CR32","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","volume":"21","author":"JP Leonard","year":"2003","unstructured":"Leonard JP, Coleman M, Ketas JC, et al. Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2003;21:3051\u20139.","journal-title":"J Clin Oncol"},{"key":"608_CR33","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","volume":"23","author":"JP Leonard","year":"2005","unstructured":"Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed\/refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:5044\u201351.","journal-title":"J Clin Oncol"},{"key":"608_CR34","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2006;24:3880\u20136.","journal-title":"J Clin Oncol"},{"key":"608_CR35","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/annonc\/mdm114","volume":"18","author":"JP Leonard","year":"2007","unstructured":"Leonard JP, Friedberg JW, Younes A, et al. A phase I\/II study of galiximab (anti-CD80) monoclonal antibody in combination with rituximab for relapsed or refractory follicular lymphoma. Ann Oncol. 2007;18:1216\u201323.","journal-title":"Ann Oncol"},{"key":"608_CR36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.V112.11.93.93","volume":"112","author":"MS Czuczman","year":"2008","unstructured":"Czuczman MS, Leonard JP, Johnson JL, et al. FLIPI score is applicable and predictive of response to upfront immunotherapy in CALGB 50402: phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab [R]. Blood. 2008;112:93 (Abstract #233).","journal-title":"Blood"},{"key":"608_CR37","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","volume":"110","author":"X Zhao","year":"2007","unstructured":"Zhao X, Lapalombella R, Joshi T, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007;110:2569\u201377.","journal-title":"Blood"},{"key":"608_CR38","first-page":"451s","volume":"27","author":"PR Baum","year":"2009","unstructured":"Baum PR, Cerveny C, Gordon B, et al. Evaluation of the effect of TRU-16, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2009;27:451s (Abstract 8571).","journal-title":"J Clin Oncol"},{"key":"608_CR39","doi-asserted-by":"crossref","unstructured":"Andritsos A, Furman RR, Flinn IW, et al. A phase 1 trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIPTM) protein in relapsed and refractory CLL: early promising clinical activity. Blood. 2009 (in press).","DOI":"10.1182\/blood.V114.22.3424.3424"},{"key":"608_CR40","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974\u20137.","journal-title":"Science"},{"key":"608_CR41","doi-asserted-by":"crossref","first-page":"766a","DOI":"10.1182\/blood.V108.11.766.766","volume":"108","author":"L Fayad","year":"2006","unstructured":"Fayad L, Patel H, Verhoef G, et al. Clinical activity of the immunoconjugate CMC_544 on B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase I study. Blood. 2006;108:766a (Abstract 2711).","journal-title":"Blood"},{"key":"608_CR42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood.V114.22.584.584","volume":"114","author":"N Dang","year":"2009","unstructured":"Dang N, Smith MR, Offner F, et al. Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544)\u00a0+\u00a0rituximab: clinical activity including survival in patients with recurrent\/refractory follicular or \u201caggressive\u201d lymphoma. Blood. 2009;114:242\u20133.","journal-title":"Blood"},{"key":"608_CR43","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","volume":"26","author":"AA Chanan-Khan","year":"2008","unstructured":"Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008;26:1544\u201352.","journal-title":"J Clin Oncol"},{"key":"608_CR44","doi-asserted-by":"crossref","first-page":"448s","DOI":"10.1200\/JCO.2008.21.1169","volume":"27","author":"TE Witzig","year":"2009","unstructured":"Witzig TE, Wiernik PH, Moore T, et al. Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma: final results of NHL-001. J Clin Oncol. 2009;27:448s (Abstract 8560).","journal-title":"J Clin Oncol"},{"key":"608_CR45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2009-07-234179","volume":"114","author":"N Fowler","year":"2009","unstructured":"Fowler N, McLaughlin P, Hagemeister FB, et al. A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin\u2019s lymphoma. Blood. 2009;114:683 (Abstract #1714).","journal-title":"Blood"},{"key":"608_CR46","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2007-07-100115","volume":"111","author":"L Chen","year":"2008","unstructured":"Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signalling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230\u20137.","journal-title":"Blood"},{"key":"608_CR47","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578\u201385.","journal-title":"Blood"},{"key":"608_CR48","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood.V114.22.682.682","volume":"114","author":"M Ogura","year":"2009","unstructured":"Ogura M, Uchida T, Maruyama D, et al. Phase I and pharmacokinetic (PK) study of everolimus (RAD-001) in patients with relapsed or refractory non-Hodgkin\u2019s lymphoma (NHL). Blood. 2009;114:682\u20133 (Abstract #1712).","journal-title":"Blood"},{"key":"608_CR49","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2008-10-182758","volume":"114","author":"IW Flinn","year":"2009","unstructured":"Flinn IW, Byrd JC, Furman RR, et al. Evidence of clinical activity in a phase 1 study of CAL-101, an oral P110\u2206 isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-cell malignancies. Blood. 2009;114:380 (Abstract #922).","journal-title":"Blood"},{"key":"608_CR50","first-page":"434s","volume":"27","author":"BD Cheson","year":"2009","unstructured":"Cheson BD, Vose JM, Bartlett NL, et al. Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2009;27:434s (Abstract 8502).","journal-title":"J Clin Oncol"},{"key":"608_CR51","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood.V114.22.1711.1711","volume":"114","author":"WH Wilson","year":"2009","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS, et al. Phase 1\/2a study of ABT-263 in relapsed or refractory lymphoid malignancies. Blood. 2009;114:682 (Abstract #1711).","journal-title":"Blood"},{"key":"608_CR52","doi-asserted-by":"crossref","unstructured":"Younes A, Vose JM, Zelenetz AD, et al. A phase 2 trial of mapatumumab in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2010 (in press).","DOI":"10.1038\/sj.bjc.6605987"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0608-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-010-0608-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0608-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T19:36:31Z","timestamp":1711568191000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-010-0608-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,24]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1007\/s12185-010-0608-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,24]]}}}